{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:26:34Z","timestamp":1787509594813,"version":"build-2736575974"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ck0106368"],"award-info":[{"award-number":["JP19ck0106368"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K06863"],"award-info":[{"award-number":["JP21K06863"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18K06979"],"award-info":[{"award-number":["JP18K06979"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP15K08325"],"award-info":[{"award-number":["JP15K08325"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19K16809"],"award-info":[{"award-number":["JP19K16809"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP17K18436"],"award-info":[{"award-number":["JP17K18436"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP16H04706"],"award-info":[{"award-number":["JP16H04706"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP25290053"],"award-info":[{"award-number":["JP25290053"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006680","name":"Takeda Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006680","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007655","name":"Aichi Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006062","name":"Foundation for the Promotion of Cancer Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Many genes responsible for Malignant mesothelioma (MM) have been identified as tumor suppressor genes and it is difficult to target these genes directly at a molecular level. We searched for the gene which showed synthetic lethal phenotype with LATS2, one of the MM causative genes and one of the kinases in the Hippo pathway. Here we showed that knockdown of SMG6 results in synthetic lethality in LATS2-inactivated cells. We found that this synthetic lethality required the nuclear translocation of YAP1 and TAZ. Both are downstream factors of the Hippo pathway. We also demonstrated that this synthetic lethality did not require SMG6 in nonsense-mediated mRNA decay (NMD) but in regulating telomerase reverse transcriptase (TERT) activity. In addition, the RNA-dependent DNA polymerase (RdDP) activity of TERT was required for this synthetic lethal phenotype. We confirmed the inhibitory effects of LATS2 and SMG6 on cell proliferation in vivo. The result suggests an interaction between the Hippo and TERT signaling pathways. We also propose that SMG6 and TERT are novel molecular target candidates for LATS2-inactivated cancers such as MM.<\/jats:p>","DOI":"10.1038\/s41420-022-01232-w","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T09:02:47Z","timestamp":1667638967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["SMG6 regulates DNA damage and cell survival in Hippo pathway kinase LATS2-inactivated malignant mesothelioma"],"prefix":"10.1038","volume":"8","author":[{"given":"Koya","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Tange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kadomatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Miida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2428-3848","authenticated-orcid":false,"given":"Yoshitaka","family":"Sekido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-1630","authenticated-orcid":false,"given":"Yuko","family":"Murakami-Tonami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,5]]},"reference":[{"key":"1232_CR1","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.jtho.2019.03.030","volume":"14","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Rimner A, Simone CB, Cho BCJ, de Perrot M, Adjei AA, et al. The use of radiation therapy for the treatment of malignant pleural mesothelioma: expert opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2019;14:1172\u201383.","journal-title":"J Thorac Oncol"},{"key":"1232_CR2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H","volume":"180","author":"SS Murthy","year":"1999","unstructured":"Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol. 1999;180:150\u20137.","journal-title":"J Cell Physiol"},{"key":"1232_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.canrad.2016.09.009","volume":"21","author":"KE Rosenzweig","year":"2017","unstructured":"Rosenzweig KE, Giraud P. Radiation therapy for malignant pleural mesothelioma. Cancer Radiotherapie. 2017;21:73\u201376.","journal-title":"Cancer Radiotherapie"},{"key":"1232_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375\u201386.","journal-title":"Lancet"},{"key":"1232_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, de Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407\u201316.","journal-title":"Nat Genet"},{"key":"1232_CR6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","volume":"34","author":"Y Sekido","year":"2013","unstructured":"Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34:1413\u20139.","journal-title":"Carcinogenesis"},{"key":"1232_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","volume":"19","author":"A Huang","year":"2020","unstructured":"Huang A, Garraway LA, Ashworth A, Weber B. Synthetic lethality as an engine for cancer drug target discovery. Nat Rev Drug Disco. 2020;19:23\u201338.","journal-title":"Nat Rev Drug Disco"},{"key":"1232_CR8","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1172\/JCI8888","volume":"104","author":"WG Kaelin Jr","year":"1999","unstructured":"Kaelin WG Jr. Choosing anticancer drug targets in the postgenomic era. J Clin Invest. 1999;104:1503\u20136.","journal-title":"J Clin Invest"},{"key":"1232_CR9","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1038\/onc.2009.295","volume":"28","author":"J Mullenders","year":"2009","unstructured":"Mullenders J, Bernards R. Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. Oncogene. 2009;28:4409\u201320.","journal-title":"Oncogene"},{"key":"1232_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.14789\/jmj.2019.65.JMJ19-LN03","volume":"65","author":"Y Murakami-Tonami","year":"2019","unstructured":"Murakami-Tonami Y. Synthetic lethality in the search for novel molecular targets in cancer therapeutics. Juntendo Med J. 2019;65:292\u20136.","journal-title":"Juntendo Med J"},{"key":"1232_CR11","doi-asserted-by":"publisher","first-page":"16484","DOI":"10.1073\/pnas.0806574105","volume":"105","author":"A Bommi-Reddy","year":"2008","unstructured":"Bommi-Reddy A, Almeciga I, Sawyer J, Geisen C, Li WL, Harlow E, et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL-\/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci USA. 2008;105:16484\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1232_CR12","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1126\/science.278.5340.1064","volume":"278","author":"LH Hartwell","year":"1997","unstructured":"Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997;278:1064\u20138.","journal-title":"Science"},{"key":"1232_CR13","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.4161\/cc.27983","volume":"13","author":"Y Murakami-Tonami","year":"2014","unstructured":"Murakami-Tonami Y, Kishida S, Takeuchi I, Katou Y, Maris JM, Ichikawa H, et al. Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells. Cell Cycle. 2014;13:1115\u201331.","journal-title":"Cell Cycle"},{"key":"1232_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/srep31615","volume":"6","author":"Y Murakami-Tonami","year":"2016","unstructured":"Murakami-Tonami Y, Ikeda H, Yamagishi R, Inayoshi M, Inagaki S, Kishida S, et al. SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells. Sci Rep. 2016;6:31615.","journal-title":"Sci Rep"},{"key":"1232_CR15","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1111\/cas.14485","volume":"111","author":"K Yamashita","year":"2020","unstructured":"Yamashita K, Kiyonari S, Tsubota S, Kishida S, Sakai R, Kadomatsu K. Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN-amplified neuroblastoma cells. Cancer Sci. 2020;111:2431\u20139.","journal-title":"Cancer Sci"},{"key":"1232_CR16","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913\u20137.","journal-title":"Nature"},{"key":"1232_CR17","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/nature06548","volume":"451","author":"SL Edwards","year":"2008","unstructured":"Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451:1111\u20135.","journal-title":"Nature"},{"key":"1232_CR18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917\u201321.","journal-title":"Nature"},{"key":"1232_CR19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrc3458","volume":"13","author":"KF Harvey","year":"2013","unstructured":"Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013;13:246\u201357.","journal-title":"Nat Rev Cancer"},{"key":"1232_CR20","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ceb.2008.10.001","volume":"20","author":"B Zhao","year":"2008","unstructured":"Zhao B, Lei QY, Guan KL. The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol. 2008;20:638\u201346.","journal-title":"Curr Opin Cell Biol"},{"key":"1232_CR21","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/cdd.2017.99","volume":"24","author":"N Furth","year":"2017","unstructured":"Furth N, Aylon Y. The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ. 2017;24:1488\u2013501.","journal-title":"Cell Death Differ"},{"key":"1232_CR22","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/cdd.2013.83","volume":"20","author":"N Reuven","year":"2013","unstructured":"Reuven N, Adler J, Meltser V, Shaul Y. The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl. Cell Death Differ. 2013;20:1330\u201340.","journal-title":"Cell Death Differ"},{"key":"1232_CR23","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1101\/gad.888601","volume":"15","author":"A Vassilev","year":"2001","unstructured":"Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD\/TEF transcription factors utilize the activation domain of YAP65, a Src\/Yes-associated protein localized in the cytoplasm. Genes Dev. 2001;15:1229\u201341.","journal-title":"Genes Dev"},{"key":"1232_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1389450114666140106095151","volume":"15","author":"XE Guo","year":"2014","unstructured":"Guo XE, Ngo B, Modrek AS, Lee WH. Targeting tumor suppressor networks for cancer therapeutics. Curr Drug Targets. 2014;15:2\u201316.","journal-title":"Curr Drug Targets"},{"key":"1232_CR25","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","volume":"71","author":"H Murakami","year":"2011","unstructured":"Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 2011;71:873\u201383.","journal-title":"Cancer Res"},{"key":"1232_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cub.2006.01.018","volume":"16","author":"CM Azzalin","year":"2006","unstructured":"Azzalin CM, Lingner J. The human RNA surveillance factor UPF1 is required for S phase progression and genome stability. Curr Biol. 2006;16:433\u20139.","journal-title":"Curr Biol"},{"key":"1232_CR27","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.4161\/cc.5.14.3093","volume":"5","author":"CM Azzalin","year":"2006","unstructured":"Azzalin CM, Lingner J. The double life of UPF1 in RNA and DNA stability pathways. Cell Cycle. 2006;5:1496\u20138.","journal-title":"Cell Cycle"},{"key":"1232_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24201-w","volume":"12","author":"GHP Ngo","year":"2021","unstructured":"Ngo GHP, Grimstead JW, Baird DM. UPF1 promotes the formation of R loops to stimulate DNA double-strand break repair. Nat Commun. 2021;12:3849.","journal-title":"Nat Commun"},{"key":"1232_CR29","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1261\/rna.034629.112","volume":"18","author":"ED Egan","year":"2012","unstructured":"Egan ED, Collins K. Biogenesis of telomerase ribonucleoproteins. RNA. 2012;18:1747\u201359.","journal-title":"RNA"},{"key":"1232_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nature08283","volume":"461","author":"Y Maida","year":"2009","unstructured":"Maida Y, Yasukawa M, Furuuchi M, Lassmann T, Possemato R, Okamoto N, et al. An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature. 2009;461:230\u2013U104.","journal-title":"Nature"},{"key":"1232_CR31","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1128\/MCB.01021-15","volume":"36","author":"Y Maida","year":"2016","unstructured":"Maida Y, Yasukawa M, Masutomi K. De novo RNA synthesis by RNA-dependent RNA polymerase activity of telomerase reverse transcriptase. Mol Cell Biol. 2016;36:1248\u201359.","journal-title":"Mol Cell Biol"},{"key":"1232_CR32","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.tig.2017.06.006","volume":"33","author":"N Jarrous","year":"2017","unstructured":"Jarrous N. Roles of RNase P and its subunits. Trends Genet. 2017;33:594\u2013603.","journal-title":"Trends Genet"},{"key":"1232_CR33","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1111\/cas.14618","volume":"111","author":"M Machitani","year":"2020","unstructured":"Machitani M, Yasukawa M, Nakashima J, Furuichi Y, Masutomi K. RNA-dependent RNA polymerase, RdRP, a promising therapeutic target for cancer and potentially COVID-19. Cancer Sci. 2020;111:3976\u201384.","journal-title":"Cancer Sci"},{"key":"1232_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15289-7","volume":"11","author":"M Yasukawa","year":"2020","unstructured":"Yasukawa M, Ando Y, Yamashita T, Matsuda Y, Shoji S, Morioka MS, et al. CDK1 dependent phosphorylation of hTERT contributes to cancer progression. Nat Commun. 2020;11:1557.","journal-title":"Nat Commun"},{"key":"1232_CR35","doi-asserted-by":"publisher","first-page":"17337","DOI":"10.1073\/pnas.0905703106","volume":"106","author":"DC DeZwaan","year":"2009","unstructured":"DeZwaan DC, Freeman BC. The conserved Est1 protein stimulates telomerase DNA extension activity. Proc Natl Acad Sci USA. 2009;106:17337\u201342.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1232_CR36","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.15252\/embj.201489947","volume":"34","author":"T Li","year":"2015","unstructured":"Li T, Shi Y, Wang P, Guachalla LM, Sun B, Joerss T, et al. Smg6\/Est1 licenses embryonic stem cell differentiation via nonsense-mediated mRNA decay. EMBO J. 2015;34:1630\u201347.","journal-title":"EMBO J"},{"key":"1232_CR37","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1093\/nar\/gkm724","volume":"35","author":"S Redon","year":"2007","unstructured":"Redon S, Reichenbach P, Lingner J. Protein RNA and protein protein interactions mediate association of human EST1A\/SMG6 with telomerase. Nucleic Acids Res. 2007;35:7011\u201322.","journal-title":"Nucleic Acids Res"},{"key":"1232_CR38","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1101\/gad.263863.115","volume":"29","author":"JC Schmidt","year":"2015","unstructured":"Schmidt JC, Cech TR. Human telomerase: biogenesis, trafficking, recruitment, and activation. Genes Dev. 2015;29:1095\u2013105.","journal-title":"Genes Dev"},{"key":"1232_CR39","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S0960-9822(03)00210-0","volume":"13","author":"BE Snow","year":"2003","unstructured":"Snow BE, Erdmann N, Cruickshank J, Goldman H, Gill RM, Robinson MO, et al. Functional conservation of the telomerase protein Est1p in humans. Curr Biol. 2003;13:698\u2013704.","journal-title":"Curr Biol"},{"key":"1232_CR40","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0955-0674(03)00040-1","volume":"15","author":"AK Taggart","year":"2003","unstructured":"Taggart AK, Zakian VA. Telomerase: what are the Est proteins doing? Curr Opin Cell Biol. 2003;15:275\u201380.","journal-title":"Curr Opin Cell Biol"},{"key":"1232_CR41","first-page":"33","volume":"28","author":"M Kitazono-Saitoh","year":"2012","unstructured":"Kitazono-Saitoh M, Takiguchi Y, Kitazono S, Ashinuma H, Kitamura A, Tada Y, et al. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines. Oncol Rep. 2012;28:33\u201340.","journal-title":"Oncol Rep"},{"key":"1232_CR42","doi-asserted-by":"publisher","first-page":"ARTN 18677","DOI":"10.1038\/s41598-02075807-x","volume":"10","author":"S Borchert","year":"2020","unstructured":"Borchert S, Suckrau PM, Walter RFH, Wessolly M, Mairinger E, Steinborn J, et al. Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma. Sci Rep. 2020;10:ARTN 18677. https:\/\/doi.org\/10.1038\/s41598-02075807-x.","journal-title":"Sci Rep"},{"key":"1232_CR43","doi-asserted-by":"publisher","first-page":"294","DOI":"10.21037\/tlcr.2020.03.26","volume":"9","author":"SY Luo","year":"2020","unstructured":"Luo SY, Kwok HH, Yang PC, Ip MS, Minna JD, Lam DC. Expression of large tumour suppressor (LATS) kinases modulates chemotherapy response in advanced non-small cell lung cancer. Transl Lung Cancer Res. 2020;9:294\u2013305.","journal-title":"Transl Lung Cancer Res"},{"key":"1232_CR44","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.3892\/ijo.2015.2948","volume":"46","author":"K Yoshikawa","year":"2015","unstructured":"Yoshikawa K, Noguchi K, Nakano Y, Yamamura M, Takaoka K, Hashimoto-Tamaoki T, et al. The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma. Int J Oncol. 2015;46:2364\u201370.","journal-title":"Int J Oncol"},{"key":"1232_CR45","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/cdd.2013.83","volume":"20","author":"N Reuven","year":"2013","unstructured":"Reuven N, Adler J, Meltser V, Shaul Y. The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl. Cell Death Differ. 2013;20:1330\u201340.","journal-title":"Cell Death Differ"},{"key":"1232_CR46","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1038\/sj.emboj.7601377","volume":"25","author":"F Glavan","year":"2006","unstructured":"Glavan F, Behm-Ansmant I, Izaurralde E, Conti E. Structures of the PIN domains of SMG6 and SMG5 reveal a nuclease within the mRNA surveillance complex. EMBO J. 2006;25:5117\u201325.","journal-title":"EMBO J"},{"key":"1232_CR47","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3987\/COM-19-14191","volume":"100","author":"H Abe","year":"2020","unstructured":"Abe H, Nhung Nguyen H, Suzuki K, Kimura Y, Hirokawa T, Murakami-Tonami Y. Synthesis and biological evaluation of NMDI14 derivatives as anti-mesothelioma agents. Heterocycles. 2020;100:253.","journal-title":"Heterocycles"},{"key":"1232_CR48","doi-asserted-by":"publisher","first-page":"e55684","DOI":"10.1371\/journal.pone.0055684","volume":"8","author":"H Tani","year":"2013","unstructured":"Tani H, Torimura M, Akimitsu N. The RNA degradation pathway regulates the function of GAS5 a non-coding RNA in mammalian cells. PLoS One. 2013;8:e55684.","journal-title":"PLoS One"},{"key":"1232_CR49","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1182\/blood-2003-12-4322","volume":"105","author":"H El-Daly","year":"2005","unstructured":"El-Daly H, Kull M, Zimmermann S, Pantic M, Waller CF, Martens UM. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood. 2005;105:1742\u20139.","journal-title":"Blood"},{"key":"1232_CR50","doi-asserted-by":"publisher","unstructured":"Jager K, Walter M. Therapeutic targeting of telomerase. Genes (Basel). 2016;7. https:\/\/doi.org\/10.3390\/genes7070039.","DOI":"10.3390\/genes7070039"},{"key":"1232_CR51","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nature08283","volume":"461","author":"Y Maida","year":"2009","unstructured":"Maida Y, Yasukawa M, Furuuchi M, Lassmann T, Possemato R, Okamoto N, et al. An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature. 2009;461:230\u2013U104.","journal-title":"Nature"},{"key":"1232_CR52","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/neuonc\/noaa207","volume":"23","author":"JW Park","year":"2021","unstructured":"Park JW, Sahm F, Steffl B, Arrillaga-Romany I, Cahill D, Monje M, et al. TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. Neuro Oncol. 2021;23:76\u201387.","journal-title":"Neuro Oncol"},{"key":"1232_CR53","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.mrfmmm.2007.06.005","volume":"625","author":"AK Khaw","year":"2007","unstructured":"Khaw AK, Silasudjana M, Banerjee B, Suzuki M, Baskar R, Hande MP. Inhibition of telomerase activity and human telomerase reverse transcriptase gene expression by histone deacetylase inhibitor in human brain cancer cells. Mutat Res. 2007;625:134\u201344.","journal-title":"Mutat Res"},{"key":"1232_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.yexmp.2006.02.004","volume":"82","author":"HJ Woo","year":"2007","unstructured":"Woo HJ, Lee SJ, Choi BT, Park YM, Choi YH. Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells. Exp Mol Pathol. 2007;82:77\u201384.","journal-title":"Exp Mol Pathol"},{"key":"1232_CR55","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1182\/blood-2003-12-4322","volume":"105","author":"H El-Daly","year":"2005","unstructured":"El-Daly H, Kull M, Zimmermann S, Pantic M, Waller CF, Martens UM. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood. 2005;105:1742\u20139.","journal-title":"Blood"},{"key":"1232_CR56","doi-asserted-by":"publisher","first-page":"22568","DOI":"10.1074\/jbc.M000622200","volume":"275","author":"K Masutomi","year":"2000","unstructured":"Masutomi K, Kaneko S, Hayashi N, Yamashita T, Shirota Y, Kobayashi K, et al. Telomerase activity reconstituted in vitro with purified human telomerase reverse transcriptase and human telomerase RNA component. J Biol Chem. 2000;275:22568\u201373.","journal-title":"J Biol Chem"},{"key":"1232_CR57","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bbrc.2020.07.132","volume":"531","author":"Z Wen","year":"2020","unstructured":"Wen Z, Wang Y, Qi S, Ma M, Li J, Yu FX. Regulation of TP73 transcription by Hippo-YAP signaling. Biochem Biophys Res Commun. 2020;531:96\u2013104.","journal-title":"Biochem Biophys Res Commun"},{"key":"1232_CR58","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/sj.onc.1210722","volume":"27","author":"K Yoshida","year":"2008","unstructured":"Yoshida K, Ozaki T, Furuya K, Nakanishi M, Kikuchi H, Yamamoto H, et al. ATM-dependent nuclear accumulation of IKK-alpha plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin. Oncogene. 2008;27:1183\u20138.","journal-title":"Oncogene"},{"key":"1232_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24201-w","volume":"12","author":"GHP Ngo","year":"2021","unstructured":"Ngo GHP, Grimstead JW, Baird DM. UPF1 promotes the formation of R loops to stimulate DNA double-strand break repair. Nat Commun. 2021;12:3849.","journal-title":"Nat Commun"},{"key":"1232_CR60","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.4161\/cc.5.14.3093","volume":"5","author":"CM Azzalin","year":"2006","unstructured":"Azzalin CM, Lingner J. The double life of UPF1 in RNA and DNA stability pathways. Cell Cycle. 2006;5:1496\u20138.","journal-title":"Cell Cycle"},{"key":"1232_CR61","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.molcel.2004.05.005","volume":"14","author":"KM Brumbaugh","year":"2004","unstructured":"Brumbaugh KM, Otterness DM, Geisen C, Oliveira V, Brognard J, Li X, et al. The mRNA surveillance protein hSMG-1 functions in genotoxic stress response pathways in mammalian cells. Mol Cell. 2004;14:585\u201398.","journal-title":"Mol Cell"},{"key":"1232_CR62","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cub.2006.01.018","volume":"16","author":"CM Azzalin","year":"2006","unstructured":"Azzalin CM, Lingner J. The human RNA surveillance factor UPF1 is required for S phase progression and genome stability. Curr Biol. 2006;16:433\u20139.","journal-title":"Curr Biol"},{"key":"1232_CR63","doi-asserted-by":"publisher","first-page":"E240","DOI":"10.1371\/journal.pbio.0020240","volume":"2","author":"J Karlseder","year":"2004","unstructured":"Karlseder J, Hoke K, Mirzoeva OK, Bakkenist C, Kastan MB, Petrini JH, et al. The telomeric protein TRF2 binds the ATM kinase and can inhibit the ATM-dependent DNA damage response. PLoS Biol. 2004;2:E240.","journal-title":"PLoS Biol"},{"key":"1232_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0897-y","volume":"9","author":"LN Nguyen","year":"2018","unstructured":"Nguyen LN, Zhao J, Cao D, Dang X, Wang L, Lian J, et al. Inhibition of TRF2 accelerates telomere attrition and DNA damage in naive CD4 T cells during HCV infection. Cell Death Dis. 2018;9:900.","journal-title":"Cell Death Dis"},{"key":"1232_CR65","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1093\/bioinformatics\/btq466","volume":"26","author":"A Lachmann","year":"2010","unstructured":"Lachmann A, Xu H, Krishnan J, Berger SI, Mazloom AR, Ma\u2019ayan A. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics. 2010;26:2438\u201344.","journal-title":"Bioinformatics"},{"key":"1232_CR66","doi-asserted-by":"publisher","unstructured":"Rouillard AD, Gundersen GW, Fernandez NF, Wang Z, Monteiro CD, McDermott MG, et al. The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database. 2016;2016. https:\/\/doi.org\/10.1093\/DATABASE\/BAW100.","DOI":"10.1093\/DATABASE\/BAW100"},{"key":"1232_CR67","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.7150\/jca.33237","volume":"10","author":"L He","year":"2019","unstructured":"He L, Wu MZ, Wang XB, Qiu XS, Wang EH, Wu GP. Tumor suppressor LKB1 inhibits both the mRNA expression and the amplification of hTERC by the phosphorylation of YAP in lung cancer cells. J Cancer. 2019;10:3632\u20138.","journal-title":"J Cancer"},{"key":"1232_CR68","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1096\/fj.201902147R","volume":"34","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Liu N, Bai J, Zhou Q, Mao J, Xu L, et al. Human telomerase reverse transcriptase is a novel target of Hippo-YAP pathway. FASEB J. 2020;34:4178\u201388.","journal-title":"FASEB J"},{"key":"1232_CR69","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","volume":"34","author":"Y Sekido","year":"2013","unstructured":"Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34:1413\u20139.","journal-title":"Carcinogenesis"},{"key":"1232_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-02248-5","volume":"21","author":"T Sato","year":"2021","unstructured":"Sato T, Nakanishi H, Akao K, Okuda M, Mukai S, Kiyono T, et al. Three newly established immortalized mesothelial cell lines exhibit morphological phenotypes corresponding to malignant mesothelioma epithelioid, intermediate, and sarcomatoid types, respectively. Cancer Cell Int. 2021;21:1\u201311.","journal-title":"Cancer Cell Int"},{"key":"1232_CR71","doi-asserted-by":"publisher","first-page":"22568","DOI":"10.1074\/jbc.M000622200","volume":"275","author":"K Masutomi","year":"2000","unstructured":"Masutomi K, Kaneko S, Hayashi N, Yamashita T, Shirota Y, Kobayashi K, et al. Telomerase activity reconstituted in vitro with purified human telomerase reverse transcriptase and human telomerase RNA component. J Biol Chem. 2000;275:22568\u201373.","journal-title":"J Biol Chem"},{"key":"1232_CR72","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/s41388-018-0417-7","volume":"38","author":"A Matsushita","year":"2019","unstructured":"Matsushita A, Sato T, Mukai S, Fujishita T, Mishiro-Sato E, Okuda M, et al. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation. Oncogene. 2019;38:1966\u201378.","journal-title":"Oncogene"},{"key":"1232_CR73","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1038\/sj.emboj.7601377","volume":"25","author":"F Glavan","year":"2006","unstructured":"Glavan F, Behm-Ansmant I, Izaurralde E, Conti E. Structures of the PIN domains of SMG6 and SMG5 reveal a nuclease within the mRNA surveillance complex. EMBO J. 2006;25:5117\u201325.","journal-title":"EMBO J"},{"key":"1232_CR74","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.yexmp.2006.02.004","volume":"82","author":"HJ Woo","year":"2007","unstructured":"Woo HJ, Lee SJ, Choi BT, Park YM, Choi YH. Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells. Exp Mol Pathol. 2007;82:77\u201384.","journal-title":"Exp Mol Pathol"},{"key":"1232_CR75","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3748\/wjg.v8.i5.827","volume":"8","author":"RG Zhang","year":"2002","unstructured":"Zhang RG, Guo LX, Wang XW, Xie H. Telomerase inhibition and telomere loss in BEL-7404 human hepatoma cells treated with doxorubicin. World J Gastroenterol. 2002;8:827\u201331.","journal-title":"World J Gastroenterol"},{"key":"1232_CR76","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/carcin\/bgw084","volume":"37","author":"T Kakiuchi","year":"2016","unstructured":"Kakiuchi T, Takahara T, Kasugai Y, Arita K, Yoshida N, Karube K, et al. Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferation. Carcinogenesis. 2016;37:1098\u2013109.","journal-title":"Carcinogenesis"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01232-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01232-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01232-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T14:04:22Z","timestamp":1667743462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01232-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,5]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1232"],"URL":"https:\/\/doi.org\/10.1038\/s41420-022-01232-w","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,5]]},"assertion":[{"value":"19 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"446"}}